← Product Code [MID](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID) · K040463 # AESKULISA CARDIOLIPIN AGM (K040463) _Aesku, Inc. · MID · May 12, 2004 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID/K040463 ## Device Facts - **Applicant:** Aesku, Inc. - **Product Code:** [MID](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID.md) - **Decision Date:** May 12, 2004 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.5660 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Intended Use AESKULISA Cardiolipin-AGM is a solid phase enzyme immunoassay employing highly purified cardiolipin plus native human ß2-glycoprotein I for the semiquantitative and qualitative detection of IgA, IgG and /or IgM antibodies against cardiolipin in human serum. Anti-cardiolipin antibodies mainly recognize specific epitopes on a complex composed of cardiolipin and ß2-glycoprotein I which are only expressed when ß2glycoprotein I interacts with cardiolipin. The assay is an aid in the diagnosis of systemic lupus erythematosus (SLE), primary and secondary anti-phospholipid syndrome (APS) and should be used in conjuction with other serological tests and clinical findings. ## Device Story AESKULISA Cardiolipin series are solid-phase enzyme immunoassays (ELISA) for detecting anti-cardiolipin antibodies in human serum. The device uses purified cardiolipin and native human ß2-glycoprotein I as antigens to capture antibodies that recognize the cardiolipin/ß2-glycoprotein I complex. Performed in clinical laboratories by trained technicians; results are interpreted by physicians alongside other serological tests and clinical findings to aid in diagnosing SLE and APS. The assay provides semiquantitative and qualitative data to support clinical decision-making regarding autoimmune disease management. ## Clinical Evidence Bench testing only. Analytical performance included precision (intra-assay CV 0.4-7.6%, inter-assay CV 0.7-9.5%), linearity (recovery 84-108.7%), and analytical sensitivity (1.0 APL/GPL/MPL/mL). Method comparison studies were conducted using 111 samples for GM assays and 81 samples for A/Check assays against predicate devices. Agreement varied by isotype: IgG (95.5% total agreement), IgM (79.3% total agreement), IgA (86.1% total agreement), and Check (89.9% total agreement). Discrepancies were analyzed against clinical diagnosis. ## Technological Characteristics Solid-phase enzyme immunoassay (ELISA). Utilizes purified cardiolipin and native human ß2-glycoprotein I as antigens. Designed for detection of IgA, IgG, and IgM antibody classes in human serum. ## Regulatory Identification A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies). ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which features three abstract human figures connected at the shoulders and facing to the right. The figures are rendered in black and have a flowing, wave-like appearance. Encircling the caduceus is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 MAY 1 2 2004 Mr. Stanley Ammons US Correspondent Aesku. Inc 8880 Northwest 18th Terrace Miami, FL 33172 k040463 Re: Trade/Device Name: AESKULISA® Cardiolipin AGM AESKULISA® Cardiolipin A AESKULISA® Cardiolipin GM AESKULISA® Cardiolipin Check Regulation Number: 21 CFR 866.5660 Regulation Name: Multiple autobodies immunological test system Regulatory Class: Class II Product Code: MID Dated: May 3, 2004 Received: May 7, 2004 Dear Mr. Ammons: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalcnt (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labcling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {1}------------------------------------------------ Page 2 If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html. Sincerely yours, Joseph L. Aralett Joseph L. Hackett, Ph.D. Acting Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## 3 Indications for use 510(k) Number (if known): Kn40463 Device Name:_AESKULISA Cardiolipin-AGM__ Indications For Use: AESKULISA Cardiolipin-AGM is a solid phase enzyme immunoassay employing highly purified cardiolipin plus native human ß2-glycoprotein I for the semiquantitative and qualitative detection of IgA, IgG and /or IgM antibodies against cardiolipin in human serum. Anti-cardiolipin antibodies mainly recognize specific epitopes on a complex composed of cardiolipin and ß2-glycoprotein I which are only expressed when ß2glycoprotein I interacts with cardiolipin. The assay is an aid in the diagnosis of systemic lupus erythematosus (SLE), primary and secondary anti-phospholipid syndrome (APS) and should be used in conjuction with other serological tests and clinical findings. Prescription Use V (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Marie Chan Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K040463 {3}------------------------------------------------ ## 510(k) Number (if known): KOHO40463 Device Name:_AESKULISA Cardiolipin-A_ Indications For Use: AESKULISA Cardiolipin-A is a solid phase enzyme immunoassay employing highly purified cardiolipin plus native human ß2-glycoprotein I for the semiquantitative and qualitative detection of IgA antibodies against cardiolipin in human serum. Anti-cardiolipin antibodies mainly recognize specific epitopes on a complex composed of cardiolipin and ß2-glycoprotein | which are only expressed when ß2-glycoprotein | interacts with cardiolipin. The assay is an aid in the diagnosis of systemic lupus erythematosus (SLE), primary and secondary anti-phospholipid syndrome (APS) and should be used in conjuction with other serological tests and clinical findings. Prescription Use ✔ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use _ (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) 1 Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Maria Chan Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety Ko 40463 510(k)________________________________________________________________________________________________________________________________________________________________________ {4}------------------------------------------------ ## 510(k) Number (if known): K040463 Device Name: AESKULISA Cardiolipin-GM Indications For Use: AESKULISA Cardiolipin-GM is a solid phase enzyme immunoassay employing highly purified cardiolipin plus native human ß2-glycoprotein I for the semiquantitative and qualitative detection of IgG and /or IgM antibodies against cardiolipin in human serum. Anti-cardiolipin antibodies mainly recognize specific epitopes on a complex composed of cardiolipin and ß2-glycoprotein I which are only expressed when ß2-glycoprotein I interacts with cardiolipin. The assay is an aid in the diagnosis of systemic lupus erythematosus (SLE), primary and secondary anti-phospholipid syndrome (APS) and should be used in conjuction with other serological tests and clinical findings. Prescription Use __ V (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Maria Chen Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k)_ Ko 40463 {5}------------------------------------------------ ## 510(k) Number (if known): 30404 (c3 Device Name: AESKULISA Cardiolipin-Check Indications For Use: AESKULISA Cardiolipin-Check is a solid phase enzyme immunoassay employing highly purified cardiolipin plus native human ß2-glycoprotein I for the combined semiquantitative and qualitative detection of IgA, IgG and IgM antibodies against cardiolipin in human serum. Anti-cardiolipin antibodies mainly recognize specific epitopes on a complex composed of cardiolipin and ß2-glycoprotein I which are only expressed when ß2glycoprotein I interacts with cardiolipin. The assay is an aid in the diagnosis of systemic lupus erythematosus (SLE), primary and secondary anti-phospholipid syndrome (APS) and should be used in conjuction with other serological tests and clinical findings. Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Mario Clon Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) Ko40463 --- **Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID/K040463](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID/K040463) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com